51665-84-0

Basic information

• Product Name: Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate
• Synonyms: Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate;METHYL 2-(6-BROMOBENZO[D][1,3]DIOXOL-5-YL)ACETATE
• CAS NO: 51665-84-0
• Molecular Formula: C₁₀H₉BrO₄
• Molecular Weight: 273.08006
• Mol File: 51665-84-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 82-84 °C(Solv: methanol (67-56-1))
• Boiling Point: 328.6°C at 760 mmHg
• Flash Point: 152.6°C
• Appearance: /
• Density: 1.61g/cm³
• Vapor Pressure: 0.000187mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate(51665-84-0)
• EPA Substance Registry System: Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate(51665-84-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 51665-84-0(Hazardous Substances Data)

Usage

General Description

Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate is a chemical compound with a molecular formula C11H9BrO4. It is an ester, specifically the methyl ester of 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetic acid. Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate is used in the synthesis of various organic and pharmaceutical compounds. It is known for its potential biological activities and pharmacological properties, making it a valuable intermediate in the production of drugs and agrochemicals. Methyl 2-(6-bromo-2H-1,3-benzodioxol-5-yl)acetate is generally stored and handled with care due to its potentially hazardous nature and must be used in accordance with proper safety protocols.

InChI:InChI=1/C10H9BrO4/c1-13-10(12)3-6-2-8-9(4-7(6)11)15-5-14-8/h2,4H,3,5H2,1H3

Upstream product

• 67-56-1 methanol 
• 5470-14-4 (6-bromobenzo[1,3]dioxol-5-yl)acetic acid 
• 2861-28-1 1,3-benzodioxole-5-acetic acid 
• 326-59-0 benzo[1,3]dioxol-5-yl-acetic acid methyl ester 

Downstream Products

• 1454883-54-5 7-(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-6-methoxyisochroman 
• 5434-50-4 2-(5-bromobenzo[d][1,3]dioxol-6-yl)acetonitrile 
• 736143-59-2 (2',3'-dimethoxy-4,5-methylendioxybiphenyl-2-yl)-N-methylacetamide 
• 184042-03-3 methyl (3,4-methylenedioxy)-6-cyanophenylacetate 

Relevant articles and documents

Enantioselective Syntheses of Strychnos and Chelidonium Alkaloids through Regio- and Stereocontrolled Cooperative Catalysis

We describe enantioselective syntheses of strychnos and chelidonium alkaloids. In the first case, indole acetic acid esters were established as excellent partner nucleophiles for enantioselective cooperative isothiourea/Pd catalyzed α-alkylation. This provides products containing indole-bearing stereocenters in high yield and with excellent levels of enantioinduction in a manner that is notably independent of the N-substituent. This led to concise syntheses of (?)-akuammicine and (?)-strychnine. In the second case, the poor performance of ortho-substituted cinnamyl electrophiles in the enantioselective cooperative isothiourea/Ir catalyzed α-alkylation was overcome by appropriate substituent choice, leading to enantioselective syntheses of (+)-chelidonine, (+)-norchelidonine, and (+)-chelamine.

Design, synthesis, and biological evaluation of platensimycin analogues with varying degrees of molecular complexity

The molecular design, chemical synthesis, and biological evaluation of two distinct series of platensimycin analogues with varying degrees of complexity are described. The first series of compounds probes the biological importance of the benzoic acid subunit of the molecule, while the second series explores the tetracyclic cage domain. The biological data obtained reveal that, while the substituted benzoic acid domain of platensimycin is a highly conserved structural motif within the active compounds with strict functional group requirements, the cage domain of the molecule can tolerate considerable structural modifications without losing biological action. These findings refine our present understanding of theplatensimycin pharmacophore and establish certain structure-activity re lationships from which the next generation of designed analogues of thisnew antibiotic may emerge.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.